Pyxis Oncology (PYXS) Gains from Sales and Divestitures (2021 - 2022)
Pyxis Oncology (PYXS) reported Gains from Sales and Divestitures of $196164.0 for Q2 2022, up 94.4% on a QoQ basis from $100908.0 in Q1 2022.
Pyxis Oncology (PYXS) has 2 years of Gains from Sales and Divestitures data on file, last reported at $196164.0 in Q2 2022.
- Quarterly Gains from Sales and Divestitures changed N/A year-over-year to $196164.0 in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $196164.0 (changed N/A YoY) and the FY2021 annual result came in at $306998.0, changed N/A from the prior year.
- Gains from Sales and Divestitures improved to $196164.0 in Q2 2022 per PYXS's latest filing, from $100908.0 in the prior quarter.
- Across five years, Gains from Sales and Divestitures topped out at $333888.0 in Q3 2021 and bottomed at $100908.0 in Q1 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Pyxis Oncology | 120.87 Mn | 103.97 Mn | 8.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 196,164.00 |
| Jun 30, 2022 | 196,164.00 |
| Mar 31, 2022 | 100,908.00 |
| Mar 31, 2022 | 100,908.00 |
| Dec 31, 2021 | 306,998.00 |
| Dec 31, 2021 | 306,998.00 |
| Sep 30, 2021 | 333,888.00 |
| Sep 30, 2021 | 333,888.00 |